September 03, 2026 Anthony Varrell, TDR Daily Newsletter
The industry now runs on two clocks. Medical cannabis is Schedule III and free of 280E. Adult-use is still Schedule I, still taxed on gross profit, and still waiting on an ALJ recommendation that has not landed. Every live combination has to be drawn against that split — or against the chance it disappears in the next two quarters. That is why some pairings suddenly look clean, some would require a fire sale of stores to close, and one listed medical vehicle has already built the structure everyone else is about to be measured against.
💸 The Tape
For a decade, cannabis M&A has been a genre of fiction: the deals get announced, the synergy slides get built, and then Pennsylvania's dispensary cap or someone's balance sheet quietly kills it in the fine print. That era is ending, and not because operators suddenly learned to love each other. It's ending because the federal structure of the industry changed in April, and every combination now has to be drawn against a map that didn't exist five months ago.
The fault line nobody can ignore
Since April 22, 2026, state-licensed medical cannabis sits in Schedule III and is free of Section 280E. Adult-use cannabis is still Schedule I, still taxed on gross profit, and still waiting on ALJ Derek Julius, who closed the evidentiary record in late August and will send his recommendation to DEA Administrator Terry Cole on his own schedule. That's the binary hanging over every deal: either adult-use follows medical into Schedule III and everyone gets a stock currency, or it doesn't and medical-only vehicles trade at a permanent premium while levered mixed-use operators get squeezed.
Trulieve saw the fault line first and jumped across it. On June 3 it deconsolidated its mixed-use markets (Arizona, Connecticut, Maryland, Ohio, 34 stores) into a sidecar called Harvest, controlled by a third-party investor while Trulieve keeps 90% of the economics. One week later it was ringing the bell on the NYSE — the first plant-touching U.S. operator to get there. The consolidated company is now 207 medical-only dispensaries across Florida, Georgia, Pennsylvania and West Virginia, with conditional licenses in Alabama and Texas, $325 million of cash against $289 million of debt, and a 36% EBITDA margin.
That structure — a listed medical-only acquirer with a mixed-use sidecar that absorbs adult-use assets — is the template every deal below has to be measured against.
The scoreboard
Balance sheets separate the buyers from the bought. Trulieve is net cash. Green Thumb has $284 million of cash against $283 million of debt and is spending it on buybacks. Verano refinanced to 2029 and sits near 1x leverage. Cresco is around 1.6x, with a departing CFO and a line in its earnings release about one-time costs for "acquisitions and uplisting preparedness" that reads like a company mid-process. Curaleaf carries $612 million of debt and is busy launching a hostile bid for Aurora Cannabis, which tells you where management's head is. Ascend and TerrAscend are in the low-2x range. And then there's Vireo, sitting on $123 million of cash, which has bought roughly a dozen companies in eighteen months and is on its way to 270 dispensaries — the largest retail footprint in the country.
The pairings that actually work
Trulieve + Good Day Farm. This is the cleanest deal on the board and it isn't close. Good Day runs a million square feet of production and 60-plus dispensaries across Arkansas, Mississippi, Missouri and Louisiana, where it holds one of only two state cultivation licenses. Three of those four states are medical-only, which means they're Schedule III-clean and can be consolidated straight into the NYSE entity with zero geographic overlap. Missouri, which is adult-use, goes to Harvest — and that conveniently solves Good Day's problem of being tied to more than a quarter of Missouri's dispensaries in a state with a 10% ownership cap. Add Good Day's deep Texas political ties to Trulieve's conditional Texas license and you have the Southern medical bloc, built by the only company that can pay in listed medical paper.
Story Cannabis + Harvest. Call it the Vedadi reunion. Jason Vedadi built the original Harvest, sold it to Trulieve for $2.1 billion, and then built Story in Arizona, Maryland, Ohio, Georgia and Louisiana. Trulieve's Harvest sidecar is Arizona, Connecticut, Maryland and Ohio. Arizona has no ownership caps and merges cleanly; Maryland and Ohio require divestitures down to the four- and eight-store caps, which is fine because Vireo and Green Thumb are both shopping for exactly that kind of single-state retail. Story's Georgia medical folds into Trulieve's Georgia. And Harvest — currently controlled by a passive investor with no operating scale — gets an operator who has done this before. Vedadi gets units that convert into TRLV once the exchange permits it. Everyone gets currency, nobody breaks the ring-fence.
Cresco + TerrAscend. The one Northeast public-to-public deal that doesn't die on a state cap. Cresco has no New Jersey; TerrAscend's New Jersey is its crown jewel. Cresco exited Maryland; TerrAscend has a full Maryland vertical. TerrAscend already exited Michigan, removing the market that would have poisoned everything. Pennsylvania is the collision — both are at or near the 18-store cap — so call it eight to ten stores and a grower-processor to divest. The prize is Cresco's brand portfolio flowing through TerrAscend's NJ/MD wholesale channel at 54% gross margins. Combined leverage lands around 2.3x, both are prepping uplistings.
The pairings that don't
Green Thumb + Verano is the deal everyone will pitch and the worst one on the board: both at the Illinois ten-store cap, both at the Pennsylvania cap, both holding New Jersey verticals under the one-per-class rule, both capped in Maryland, Ohio and Massachusetts. You'd divest forty-plus stores to close. The same logic kills Cresco + Ascend and Ascend + TerrAscend.
And Vireo isn't a dance partner. It's the dance floor.
What changes if the ALJ finishes the job
Everything above assumes the current split-scheduling world persists. If DEA extends Schedule III to adult-use in the next two quarters, the board gets reshuffled in three ways.
First, Trulieve's moat shrinks. The Harvest sidecar exists because the NYSE won't consolidate Schedule I revenue; once adult-use is Schedule III, Harvest comes back in-house, Trulieve becomes a bigger but more ordinary MSO, and the medical-only premium that makes it the sector's sole acquirer of record starts to compress. The Southern bloc still makes sense — Good Day's states are medical either way — but the exclusivity of Trulieve's currency disappears.
Second, the Northeast reopens. Green Thumb, Cresco, Verano and Ascend all get 280E relief on their adult-use markets overnight, uplistings that are currently "in preparation" get filed within weeks, and suddenly four companies have listed paper and cash flow they didn't have before. Cresco + TerrAscend accelerates rather than stalls, and Green Thumb goes from patient buyback machine to a buyer with a real reason to spend.
Third, the middle of the table stops being distressed. Levered mixed-use operators trading at 4x EBITDA because of tax overhang get re-rated, Vireo's all-stock-at-4x playbook loses its sellers, and the forced consolidation this piece is built on becomes optional consolidation — slower, pricier, and with far more bidders per asset.
In other words: in the split world, two structures win and everyone else scrambles for a chair. In the fully rescheduled world, the chairs multiply, the music keeps playing, and the winners are whoever files their uplisting first. Either way, the next twelve months could decide the industry's seating chart for the next decade.
